Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org


Molecular Profile Unknown unknown
Therapy Carboplatin + Paclitaxel + RO4929097
Indication/Tumor Type triple-receptor negative breast cancer
Response Type not applicable

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown triple-receptor negative breast cancer not applicable Carboplatin + Paclitaxel + RO4929097 Phase I Actionable In a Phase I trial, the combination of RO4929097 (RG-4733), Paraplatin (carboplatin), and Taxol (paclitaxel) demonstrated safety and resulted in a pathologic complete response in 36% (5/14) of patients with triple receptor-negative breast cancer; however, this trial as well as further development of RO4929097 (RG-4733) were discontinued due to the limited clinical efficacy observed in other cancer types (PMID: 31953695). 31953695
PubMed Id Reference Title Details
(31953695) A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer. Full reference...